AI Article Synopsis
- CAR-T therapy has been effective for treating B cell lymphomas and leukaemias, leading to interest in its application for T cell malignancies.
- The treatment faces significant challenges, particularly because the target antigens are often found on both malignant and normal T cells, which can result in unintended damage to healthy cells.
- The review explores the latest clinical data on CAR-T treatment for T-ALL and T cell lymphomas, aiming to identify insights for future research and therapeutic strategies.
Article Abstract
Chimeric antigen receptor T cell (CAR-T) therapy has proven successful for B cell lymphomas and leukaemias. This success has inspired the development of CAR-T for T cell malignancies. T cell lymphomas and T-ALL are highly heterogenous diseases but are united by poor prognosis in the relapsed/refractory (r/r) setting and the lack of any novel, targeted therapies. CAR-T therapy is a promising solution for these diseases but carries a number of challenges, principally that target antigens are typically shared between malignant and normal T cells. This can cause issues with fratricide and T cell aplasia. In this review we discuss the current state of CAR-T treatment for T-ALL and T cell lymphomas, highlighting recent novel clinical data for T cell malignancies and discuss lessons that can be learned for future research in this area.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/bloodadvances.2023012263 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!